Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors

BACKGROUND: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte−associated protein 4 (CTLA-4) and programmed cell death 1 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Seethapathy, Harish, Zhao, Sophia, Strohbehn, Ian A., Lee, Meghan, Chute, Donald F., Bates, Halla, Molina, Gabriel E., Zubiri, Leyre, Gupta, Shruti, Motwani, Shveta, Leaf, David E., Sullivan, Ryan J., Rahma, Osama, Blumenthal, Kimberly G., Villani, Alexandra-Chloe, Reynolds, Kerry L., Sise, Meghan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569697/
https://www.ncbi.nlm.nih.gov/pubmed/33102962
http://dx.doi.org/10.1016/j.ekir.2020.07.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569697/
https://www.ncbi.nlm.nih.gov/pubmed/33102962
http://dx.doi.org/10.1016/j.ekir.2020.07.011

Ejemplares similares